Skip to main content

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • FDA launches major push to repurpose existing drugs for rare and chronic diseases

    The U.S. Food and Drug Administration (FDA) has announced a new initiative aimed at accelerating the repurposing of already approved medicines to treat diseases with significant unmet medical needs, including rare disorders, neurodegenerative diseases, metabolic conditions, and substance use disorders.

  • OneSource Specialty Pharma Limited reports strong Q4 FY26 recovery, reaffirms FY28 growth guidance

    OneSource Specialty Pharma Limited has announced a strong recovery in its fourth quarter performance for FY26, driven by growth across all major business segments and the commercial launch of semaglutide products in India. The company also reaffirmed its FY28 guidance of achieving nearly USD 400 million in organic revenue with around 40% EBITDA margin.

  • Biogen Completes acquisition of Apellis Pharmaceuticals

    -- Biogen Inc. (Nasdaq: BIIB) today announced the successful completion of the acquisition of Apellis Pharmaceuticals, Inc. (Nasdaq: APLS). Apellis, a leader in advancing treatments for serious, complement-driven diseases, is now a wholly owned subsidiary of Biogen.

  • GLP-1 Obesity Drugs May Reduce Fat While Preserving Muscle, Study Finds
    A new real-world study presented at the European Congress on Obesity 2026 suggests that popular obesity medications such as semaglutide and tirzepatide may help patients lose mostly fat while preserving much of their muscle mass.
  • Heart Attack Survivors May Face Faster Memory Decline, New Study Warns

    People who have survived a heart attack could be at a greater risk of experiencing faster declines in memory and thinking abilities as they age, according to a new study published in the journal Stroke.

    Researchers found that adults with a prior heart attack had a significantly higher likelihood of developing cognitive impairment over time compared to individuals without a history of heart attack. The findings highlight a growing connection between heart health and brain health, especially among older adults.

  • FDA Approves BeOne’s BEQALZI for Blood Cancer
    BeOne Medicines Ltd. a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to BEQALZI™ (bee-KAHL-zee; sonrotoclax), a foundational, next-generation BCL2 inhibitor, for the treatment of adult patients with relapsed or refractory (R/R) mantle cell lymphoma
  • AstraZeneca’s Imfinzi Combination Shows Survival Benefit in Bladder Cancer Trial
    High-level results from a planned interim analysis of the VOLGA Phase III trial showed perioperative treatment with Imfinzi (durvalumab) in combination with neoadjuvant enfortumab vedotin (EV) demonstrated statistically significant and clinically meaningful improvements in event-free survival (EFS) and overall survival (OS) in patients with muscle-invasive bladder cancer (MIBC) versus standard of care.
  • Blocking TGF-β Signaling May Strengthen Efficacy of Osteoporosis Therapy

    A recent mouse model based study suggests that blocking TGF-β may improve osteoporosis treatment by helping quiescent osteoblasts in inactive bone surfaces return to an active state. Using spatial transcriptomics, single-cell analysis, and functional experiments, researchers identified TGF-β signaling as a regulator of osteoblast activation. In a bone-loss mouse model, dual inhibition of TGF-β and sclerostin increased bone mass more effectively than sclerostin inhibition alone, highlighting a promising combination strategy.

  • Garlic-Derived Compound Shows Potential to Improve Muscle Health During Aging

    A surprising breakthrough in anti-aging research raises hopes of delaying muscle aging and weakness by harnessing the potential of a garlic-derived compound, S-1-propenyl-L-cysteine (S1PC). Researchers identify a key role for S1PC in orchestrating a key inter-organ communication between fat tissue and the hypothalamus in the brain, thus supporting muscle function in aged mice. Elements of this signaling mechanism were also observed in humans, highlighting the potential of S1PC-based anti-aging interventions.

  • What Lies behind Hereditary Heart Rhythm Disorders

    Short QT syndrome is a genetic disease that leads to sudden cardiac death at a young age. Mutations in the SLC4A3 gene, which regulates bicarbonate-chloride exchange, were recently described as a potential cause. An international research team including a group from Ruhr University Bochum, Germany, investigated this possibility. The researchers discovered how different variants of the gene affect heart muscle cells: Specifically, the pH level increased and the flow of ion channels was altered. This insight could aid in providing better personal care for persons affected by the disease.

Subscribe to Pharma News